The EEF1E1 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population designed for loss-of-function studies of the EEF1E1 gene in a human non-small cell lung carcinoma background. This heterogeneous pool of NCI-H1299 cells harbors a disrupted EEF1E1 locus via CRISPR-mediated genome editing, enabling investigation of gene function without clonal selection biases. As a polyclonal knockout model, it preserves population-level diversity while establishing a null genetic background, offering a robust system for pooled functional genomics, drug screening, and mechanistic dissection of EEF1E1-dependent processes.
The host cell line, NCI-H1299, is an epithelial line derived from lymph node metastasis of non-small cell lung carcinoma, widely used as a model of metastatic lung adenocarcinoma. NCI-H1299 cells are homozygous for a partial TP53 deletion, lacking functional p53, which abrogates canonical p53-mediated DNA damage responses. This p53-null background enables study of p53-independent tumor suppressor mechanisms and evaluation of therapies bypassing p53.
EEF1E1 encodes AIMP3, a core component of the multi-aminoacyl-tRNA synthetase complex that facilitates translation elongation by delivering charged tRNAs to the ribosome. Upon genotoxic stress from UV radiation or reactive oxygen species, AIMP3 dissociates from the complex and translocates to the nucleus. There, it stabilizes p53 by disrupting the MDM2-p53 negative feedback loop, leading to transcriptional upregulation of p21, BAX, and PUMA. This tumor-suppressive signaling involves upstream kinases ATM and ATR, and other synthetase complex members AIMP1/p43, AIMP2/p38, KARS, and MARS.
In the p53-deficient NCI-H1299 context, knockout of EEF1E1 provides a unique tool to dissect AIMP3 functions independent of its canonical p53 stabilization activity. While the loss of p53 negates downstream checkpoint activation, this model enables investigation of AIMP3??s roles in translation regulation, DNA damage sensing, and potentially p53-independent apoptosis or senescence pathways. The lung cancer origin further positions this system to explore how loss of AIMP3 impacts non-small cell lung carcinoma biology, including proliferation, migration, and response to chemotherapeutics that induce genotoxic stress.
Researchers can employ these polyclonal knockout cells in a variety of experimental workflows. Western blotting and immunofluorescence confirm AIMP3 ablation and assess the expression of p21 or BAX under conditions of exogenous p53 reconstitution or stress. Co-immunoprecipitation assays permit mapping of interactions between AIMP3 and remaining synthetase complex components. Translation efficiency can be evaluated via polysome profiling, while cell viability and drug sensitivity assays with DNA-damaging agents (e.g., cisplatin, etoposide) reveal chemoresistance mechanisms. This model is well suited for functional genomics screens, structure-function analyses of the aminoacyl-tRNA synthetase complex, and preclinical evaluation of novel therapeutics targeting translation or p53-independent death pathways in lung cancer. For further details, contact Ascent Research.
